↓ Skip to main content

FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer

Overview of attention for article published in BMC Cancer, October 2009
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
47 Dimensions

Readers on

mendeley
62 Mendeley
Title
FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer
Published in
BMC Cancer, October 2009
DOI 10.1186/1471-2407-9-355
Pubmed ID
Authors

Gareth O Griffiths, Sarah Burns, Simon I Noble, Fergus R Macbeth, David Cohen, Timothy S Maughan

Abstract

Venous thromboembolism (VTE) occurs when blood clots in the leg, pelvic or other deep vein (deep vein thrombosis) with or without transport of the thrombus into the pulmonary arterial circulation (pulmonary embolus). VTE is common in patients with cancer and is increased by surgery, chemotherapy, radiotherapy and disease progression. Low molecular weight heparin (LMWH) is routinely used to treat VTE and some evidence suggests that LMWH may also have an anticancer effect, by reduction in the incidence of metastases. The FRAGMATIC trial will assess the effect of adding dalteparin (FRAGMIN), a type of LMWH, to standard treatment for patients with lung cancer.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Jamaica 1 2%
United Kingdom 1 2%
France 1 2%
Unknown 59 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 15 24%
Researcher 11 18%
Student > Ph. D. Student 8 13%
Other 5 8%
Student > Doctoral Student 4 6%
Other 13 21%
Unknown 6 10%
Readers by discipline Count As %
Medicine and Dentistry 26 42%
Nursing and Health Professions 8 13%
Agricultural and Biological Sciences 7 11%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Psychology 3 5%
Other 7 11%
Unknown 7 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2012.
All research outputs
#7,762,229
of 12,372,945 outputs
Outputs from BMC Cancer
#2,220
of 4,558 outputs
Outputs of similar age
#140,747
of 258,291 outputs
Outputs of similar age from BMC Cancer
#103
of 216 outputs
Altmetric has tracked 12,372,945 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,558 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 258,291 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 216 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.